ImetelChat

I was hoping for postive results from the IMPRESS study... anyone else?

ASCO late breaking abstract process.....per their online guidelines. I am hoping the submitted abstracts are placeholders with more to come...

The ASCO late-breaking data policy allows for the submission of late-breaking data only for: Randomized phase II and III trials for which no preliminary ...

Essentially, the EMA has adopted the proposed changes to the Pediatric Investigational Plan to allow a clinical trial for children with MDS, JMML and AML to commence as of Nov 13, 2023. The trial will have several stages where imetelstat is used in combination with 2 different chemotherapeutics ...

2035 is the date of completion of the investigation plan. Someone mentioned that clinical trials were starting this month. Does anyone have any more information about where the clinical trials are starting for AML in the pediatric population?

I can see all of the documents referenced, but is Imetelstat use in the pediatric population still deferred until 2035?